US 11,963,714 B2
Methods and apparatus for renal neuromodulation
Mark E. Deem, Mountain View, CA (US); Hanson S. Gifford, III, Woodside, CA (US); Denise Zarins, Saratoga, CA (US); Douglas Sutton, Pacifica, CA (US); Erik Thai, Mountain View, CA (US); Mark Gelfand, New York, NY (US); and Howard R. Levin, Teaneck, NJ (US)
Assigned to Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed by Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed on Jun. 14, 2021, as Appl. No. 17/347,179.
Application 11/782,451 is a division of application No. 11/129,765, filed on May 13, 2005, granted, now 7,653,438, issued on Jan. 26, 2010.
Application 17/347,179 is a continuation of application No. 16/271,728, filed on Feb. 8, 2019, granted, now 11,033,328.
Application 16/271,728 is a continuation of application No. 15/946,919, filed on Apr. 6, 2018, granted, now 10,245,429, issued on Apr. 2, 2019.
Application 15/946,919 is a continuation of application No. 15/667,781, filed on Aug. 3, 2017, abandoned.
Application 15/667,781 is a continuation of application No. 15/141,764, filed on Apr. 28, 2016, abandoned.
Application 15/141,764 is a continuation of application No. 15/019,793, filed on Feb. 9, 2016, granted, now 9,675,413, issued on Jun. 13, 2017.
Application 15/019,793 is a continuation of application No. 14/636,317, filed on Mar. 3, 2015, granted, now 9,289,255, issued on Mar. 22, 2016.
Application 14/636,317 is a continuation of application No. 14/056,888, filed on Oct. 17, 2013, granted, now 9,125,661, issued on Sep. 8, 2015.
Application 14/056,888 is a continuation of application No. 13/930,863, filed on Jun. 28, 2013, granted, now 8,852,163, issued on Oct. 7, 2014.
Application 13/930,863 is a continuation of application No. 13/619,851, filed on Sep. 14, 2012, granted, now 8,548,600, issued on Oct. 1, 2013.
Application 13/619,851 is a continuation of application No. 12/777,892, filed on May 11, 2010, granted, now 8,768,470, issued on Jul. 1, 2014.
Application 12/777,892 is a continuation of application No. 11/782,451, filed on Jul. 24, 2007, abandoned.
Application 11/129,765 is a continuation in part of application No. 10/408,665, filed on Apr. 8, 2003, granted, now 7,162,303, issued on Jan. 9, 2007.
Claims priority of provisional application 60/624,793, filed on Nov. 2, 2004.
Claims priority of provisional application 60/616,254, filed on Oct. 5, 2004.
Claims priority of provisional application 60/442,970, filed on Jan. 29, 2003.
Claims priority of provisional application 60/415,575, filed on Oct. 3, 2002.
Claims priority of provisional application 60/370,190, filed on Apr. 8, 2002.
Prior Publication US 2021/0298826 A1, Sep. 30, 2021
Int. Cl. A61B 18/14 (2006.01); A61B 8/08 (2006.01); A61B 8/12 (2006.01); A61B 18/00 (2006.01); A61B 18/12 (2006.01); A61B 18/18 (2006.01); A61M 5/14 (2006.01); A61M 25/00 (2006.01); A61N 1/04 (2006.01); A61N 1/05 (2006.01); A61N 1/18 (2006.01); A61N 1/20 (2006.01); A61N 1/32 (2006.01); A61N 1/36 (2006.01); A61N 5/00 (2006.01); A61N 7/00 (2006.01)
CPC A61B 18/1492 (2013.01) [A61B 8/0891 (2013.01); A61B 8/12 (2013.01); A61B 18/1206 (2013.01); A61B 18/1233 (2013.01); A61B 18/18 (2013.01); A61M 5/14 (2013.01); A61M 25/0023 (2013.01); A61N 1/05 (2013.01); A61N 1/0551 (2013.01); A61N 1/18 (2013.01); A61N 1/205 (2013.01); A61N 1/327 (2013.01); A61N 1/36007 (2013.01); A61N 1/36017 (2013.01); A61N 1/36057 (2013.01); A61N 1/36103 (2013.01); A61N 1/36114 (2013.01); A61N 1/36139 (2013.01); A61N 5/00 (2013.01); A61N 7/00 (2013.01); A61B 2018/00071 (2013.01); A61B 2018/00214 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00505 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00904 (2013.01); A61B 2018/126 (2013.01); A61B 2018/1467 (2013.01); A61N 1/0412 (2013.01); A61N 1/326 (2013.01); A61N 1/36117 (2013.01); A61N 2007/0021 (2013.01); A61N 2007/003 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method comprising:
intravascularly advancing an elongate shaft of a catheter to renal vasculature of a patient;
locating a distal portion of the elongate shaft of the catheter within a renal vessel of the patient, wherein the distal portion carries at least one neuromodulation element, and wherein each neuromodulation element comprises a corresponding needle port and a corresponding needle;
imaging at least one radiopaque marker associated with the distal portion of the elongate shaft;
orienting the needle port of the at least one neuromodulation element based on the imaging of the at least one radiopaque marker;
after orienting the needle port based on the imaging, extending the corresponding needle of each of the at least one neuromodulation element to penetrate a wall of the renal vessel; and
modulating nerve tissue within an anatomical region extending about the renal vessel via the neuromodulation element.